Nestlé has completed its sale of 24.8% of Alcon’s issued and outstanding capital to Novartis following the conclusion of the regulatory process.
Go deeper with GlobalData
The cash transaction concerns 74 million Alcon shares at US$143 per share, with an aggregate value of $10.4bn after dividend adjustment.
The sale will have no capital gains tax impact on Nestlé which retains close to 52% of Alcon’s issued and outstanding capital and continues to fully consolidate Alcon.
The proceeds of the transaction will be used to reduce debt as Nestlé pursues its on-going share buy-back programme.
As announced on 7 April, Nestlé has a put option and Novartis a call option exercisable in the period from January 2010 to July 2011 on the remaining Alcon shares owned by Nestlé.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
